Evidence map›Paper›PMID 39285136›Full record

ReviewCNS drugs2024

Early Disease-Modifying Treatments for Presymptomatic Multiple Sclerosis.

Burcu Zeydan, Christina J Azevedo, Naila Makhani, Mikael Cohen, Melih Tutuncu, Eric Thouvenot, Aksel Siva, Darin T Okuda, Orhun H Kantarci, Christine Lebrun-Frenay

Abstract readReview
In one paragraph

Review in CNS drugs, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Burcu ZeydanDepartment of Radiology, Mayo Clinic, 200 First Street, SW, Rochester, MN, USA. zeydan.burcu@mayo.edu.ORCID 0000-0002-2270-9868
Christina J AzevedoKeck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Naila MakhaniDepartment of Pediatrics, Yale School of Medicine, New Haven, CT, USA.
Mikael CohenDepartment of Neurology, MS Clinic Nice, Pasteur 2 University Hospital, UR2CA-URRIS, Côte d'Azur University, Nice, France.
Melih TutuncuDepartment of Neurology, Istanbul University Cerrahpasa School of Medicine, Istanbul, Türkiye.
Eric ThouvenotDepartment of Neurology, Nîmes University Hospital Center, Univ. Montpellier, Nîmes, France.
Aksel SivaDepartment of Neurology, Istanbul University Cerrahpasa School of Medicine, Istanbul, Türkiye.
Darin T OkudaNeuroinnovation Program and Multiple Sclerosis and Neuroimmunology Imaging Program, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Orhun H KantarciDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Christine Lebrun-FrenayDepartment of Neurology, MS Clinic Nice, Pasteur 2 University Hospital, UR2CA-URRIS, Côte d'Azur University, Nice, France.

Funding

Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's DiseaseU54AG044170 · NIA · MAYO CLINIC ROCHESTER · PI MIELKE, MICHELLE M · 2018 to 2022
$7.7M
Mayo Clinic Building Interdisciplinary Research Careers in Women’s HealthK12AR084222 · NIAMS · MAYO CLINIC ROCHESTER · PI KANTARCI, KEJAL · 2023 to 2024
$733k
NIAMS NIH HHS K12 AR084222NIA NIH HHS U54 AG044170
6 · The paper itself

Abstract

Radiologically isolated syndrome (RIS) is the earliest stage in the disease continuum of multiple sclerosis (MS). RIS is discovered incidentally in individuals who are asymptomatic but have typical lesions in the brain and/or spinal cord suggestive of demyelination. The 2009 and revised 2023 RIS criteria were developed for diagnosis. Presymptomatic individuals who fulfill the 2009 RIS criteria by having 3-4 of 4 dissemination in space McDonald 2005 MS criteria are still diagnosed with RIS using the revised 2023 RIS criteria. In presymptomatic individuals who do not fulfill the 2009 RIS criteria, the revised 2023 RIS criteria target to secure an accurate and timely diagnosis: In addition to (a) having one lesion in two of four locations (periventricular, juxtacortical/cortical, infratentorial, spinal cord), (b) two of three features (spinal cord lesion, cerebrospinal fluid (CSF)-restricted oligoclonal bands, and new T2 or gadolinium-enhancing lesion) should be fulfilled. Among laboratory biomarkers, CSF kappa-free light chain can also increase diagnostic accuracy. Once the diagnosis is confirmed, the established risk factors, including demographics, imaging, and laboratory biomarkers, should be evaluated for symptomatic MS transition and prognosis. Younger age, male sex, increased neurofilament-light chain, CSF abnormality, and the presence of infratentorial, spinal cord, or gadolinium-enhancing lesions on imaging are the main risk factors for transition to symptomatic MS. Two randomized clinical trials showed significant efficacy of disease-modifying treatments in delaying or preventing the development of the first clinical event in RIS. However, because some individuals remain as RIS, it is crucial to identify the individuals with a higher number of risk factors to optimize disease outcomes by early intervention while minimizing adverse events. Discussing each RIS case with an expert MS team is recommended because there is still a lack of clinical guidelines to improve care, counseling, and surveillance.

Indexed as

Multiple SclerosisBiomarkersDisease ProgressionHumansBiomarkers

Identifiers

PMID39285136
PMCPMC11560559

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.